Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-03-29
2011-03-29
Blanchard, David J. (Department: 1643)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C424S133100, C424S141100, C424S155100, C424S178100, C435S069600, C435S235100, C435S320100, C435S328000, C530S387300, C530S388100, C530S388800, C530S391300
Reexamination Certificate
active
07915396
ABSTRACT:
Humanized anti-TAG-72 CC49 monoclonal antibodies are disclosed herein. The antibodies include a light chain Complementarity Determining Region (L-CDR)1, a L-CDR2, and a L-CDR3; and a heavy chain Complementarity Determining Region (H-CDR)1, a H-CDR2, and a H-CDR3 from humanized antibody HuCC49V10. The L-CDR1, L-CDR2, L-CDR3 are within a HuCC49V10 light chain framework region that includes the corresponding amino acid from LEN at position 5, 19, 21, and 106 in the light chain. The H-CDR1, H-CDR2, and H-CDR3 are within a heavy chain HuCC49V10 framework comprising a human 21/28′ CL residue at positions 20, 38, 48, 66, 67, 69, and 80 in the heavy chain. These humanized CC49 antibodies retain binding affinity for TAG-72 and have reduced immunogenicity, as compared to a parental HuCC49V10 antibody. Methods are disclosed herein for using these antibodies in the treatment or diagnosis of a tumor, such as a carcinoma, expressing TAG-72.
REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5472693 (1995-12-01), Gourlie et al.
patent: 5482040 (1996-01-01), Martin, Jr.
patent: 5512443 (1996-04-01), Schlom et al.
patent: 5534254 (1996-07-01), Huston et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5618920 (1997-04-01), Robinson et al.
patent: 5688657 (1997-11-01), Tsang et al.
patent: 5976531 (1999-11-01), Mezes et al.
patent: 5976845 (1999-11-01), Mezes et al.
patent: 5994511 (1999-11-01), Lowman et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6333405 (2001-12-01), Anderson et al.
patent: 6495137 (2002-12-01), Mezes et al.
patent: 2131355 (1996-03-01), None
patent: 2068593 (2003-07-01), None
patent: 0239400 (1987-09-01), None
patent: 0365997 (1990-05-01), None
patent: WO 89/00692 (1989-01-01), None
patent: WO 89/01783 (1989-03-01), None
patent: WO 90/04410 (1990-05-01), None
patent: WO 91/00295 (1991-01-01), None
patent: WO 93/12231 (1993-06-01), None
patent: WO 96/13594 (1996-05-01), None
patent: WO 97/26010 (1997-07-01), None
patent: WO 98/18809 (1998-05-01), None
patent: WO 99/43816 (1999-09-01), None
patent: WO 00/26394 (2000-05-01), None
patent: WO 2004/003155 (2004-01-01), None
Fundamental Immunology, William E. Paul, M.D. ed., 3rd ed., p. 242, 1993.
Abergel et al., “Crystallographic Studies and Primary Structure of the Antitumor Monoclonal CC49 Fab',”Proteins: Structure, Function, and Genetics17:438-443, 1993.
Berzofsky et al., p. 242,Fundamental Immunology, Paul (Ed.) Raven Press, NY, 1993.
Colcher et al., “Radioimmunolocalization of Human Carcinoma Xenografts with B72.3 Second Generation Monoclonal Antibodies,”Cancer Research48:4597-4603, 1988.
De Pascalis et al., “Generation of minimally immunogenic high affinity variants of humanized anti-carcinoma antibody HuCC49V10 by in vitro affinity maturation,”Proceedings of the American Association for Cancer Research, 44(2):1115-1116, 2003.
De Pascalis et al., “In Vitro Affinity Maturation of a Specificity-Determining Region-Grafted Humanized Anticarcinoma Antibody: Isolation and Characterization of Minimally Immunogenic High-Affinity Variants,”Clinical Cancer Research, 9:5521-5531, 2003.
Divgi et al., “Clinical Comparison of Radiolocalization of Two Monoclonal Antibodies (mAbs) Against the TAG-72 Antigen,”Nucl. Med. Biol. 21(1):9-15, 1994.
Gonzales et al., “Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues,”Molecular Immunology, 40(6):337-349, 2003.
Gonzales et al., “Reducing the potential immunogenicity of humanized CC49 by genetic manipulation of framework residues,”Proceedings of the American Association for Cancer Research, 44:1118, 2003.
Hakimi et al., “Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys,”J. Immunol. 147:1352-1359, 1991.
Hand et al., “Potential for Recombinant Immunoglobulin Constructs in the Management of Carcinoma,”Cancer Supplement73(3):1105-1113, 1994.
Iwahashi et al., “CDR Substitutions of a Humanized Monoclonal Antibody (CC49): Contributions of Individual CDRs to Antigen Binding and Immunogenicity,”Molecular Immunology36:1079-1091, 1999.
Johnson et al., “Analysis of a Human Tumor-associated Glycoprotein (TAG-72) Identified by Monoclonal Antibody B72.3,”Cancer Research46:850-857, 1986.
Jones et al., “Replacing the Complementarity-determining Regions in a Human Antibody with those from a Mouse,”Nature321:522-525, 1986.
Kashmiri et al., Chapter 21 inMethods in Molecular Biology, vol. 248: Antibody Engineering: Methods and Protocols, p. 361-376; Lo (ed.), Humana Press, Inc., Tolowa, NJ, 2003.
Kashmiri et al., “Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49,”Crit. Rev. Oncol. Hematol. 38:3-16, 2001.
Kashmiri et al, “Generation, Characterization, and in Vivo Studies of Humanized Anticarcinoma Antibody CC49,”Hybridoma14(5):461-473, 1995.
Kashmiri et al., “SDR grafting—a new approach to antibody humanization,”Methods, 36:25-34, 2005.
Mulligan et al., “Phase I Study of Intravenous177Lu-labeled CC49 Murine Monoclonal Antibody in Patients with Advanced Adenocarcinoma,”Clinical Cancer Research1:1447-1454, 1995.
Muraro et al., “Generation and Characterization of B72.3 Second Generation Monoclonal Antibodies Reactive with the Tumor-associated Glycoprotein 72 Antigen,”Cancer Research48:4588-4596, 1988.
Padlan, “A Possible Procedure for Reducing the Immunogenicity of Antibody Variable Domains while Preserving their Ligand-binding Properties,”Molecular Immunology28(4/5):489-498, 1991.
Padlan, “Anatomy of the antibody molecule,”Mol. Immunol. 31:169-217, 1994.
Padlan et al., “Identification of Specificity-determining Residues in Antibodies,”The FASEB Journal9:133-139, 1995.
Riechman et al., “Reshaping human antibodies for therapy,”Nature(London) 332:323-327, 1988.
Rixon et al., “Preferential Use of a H Chain V Region in Antitumor-associated Glycoprotein-72 Monoclonal Antibodies,”The Journal of Immunology151(11):6559-6568, 1993.
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,”PNAS79(6):1979-1983, 1982.
Saldanha et al., “A single backmutation in the human kIV framework of a previously unsuccessfully humanized antibody restores the binding activity and increases the secretion in cos cells,”Mol. Immunol. 36:709-719, 1999.
Schier et al., “Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site,”J. Mol. Biol. 263:551-567, 1996.
Sha et al., “A Heavy-chain Grafted Antibody that Recognizes the Tumor-associated TAG72 Antigen,”Cancer Biotherapy9(4):341-349, 1994.
Sharkey et al., “Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies,”Cancer Res. 55:5935s-5945s, 1995.
Slavin-Chiorini et al., “A CDR-grafted (humanized) domain-deleted antitumor antibody,”Cancer Biother. Radiopharm. 12:305-316, 1997.
Slavin-Chiorini et al., “Biological Properties of Chimeric Domain-deleted Anticarcinoma Immunoglobulins,”Cancer Research(Supplement) 55:5957s-5967s, 1995.
Tamura et al., “Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-determining Residues (SDRs) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs Only,”Journal of Immunology164(3):1432-1441, 2000.
Wu et al., “Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues,”J. Mol. Biol. 294:151-162, 1999.
Xiang et al., “The Tyrosine Residue at Position 97 in
Kashmiri Syed V. S.
Padlan Eduardo A.
Schlom Jeffrey
Blanchard David J.
Klarquist & Sparkman, LLP
The United States of America as represented by the Secretary of
LandOfFree
Nucleic acid molecules encoding minimally immunogenic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acid molecules encoding minimally immunogenic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acid molecules encoding minimally immunogenic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2628616